Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
Edited Transcript of VRAY earnings conference call or presentation 30-Apr-20 8:30pm GMT
07:34am, Friday, 01'st May 2020
Q1 2020 ViewRay Inc Earnings Call
AtriCure Inc (ATRC) Q1 2020 Earnings Call Transcript
03:00pm, Thursday, 30'th Apr 2020
ATRC earnings call for the period ending March 31, 2020.
AtriCure Announces Investor Update Webcast on May 8, 2020 in Conjunction with the 41st Annual Heart Rhythm Society (HRS) Virtual Meeting
12:30pm, Thursday, 30'th Apr 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will host an analyst and in
Needham Believes Atricure (NASDAQ: ATRC) Won’t Stop Here
10:31am, Thursday, 30'th Apr 2020
Needham analyst Michael Matson reiterated a Buy rating on Atricure (ATRC – Research Report) today and set a price target
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Blueprint Medicines (BPMC)
10:29am, Thursday, 30'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC) and Blueprint Medicines (BPMC) with bullish
Stock Traders Buy Large Volume of Call Options on AtriCure (NASDAQ:ATRC)
06:18am, Thursday, 30'th Apr 2020
AtriCure Inc. (NASDAQ:ATRC) was the recipient of unusually large options trading activity on Wednesday. Traders bought 2,279 call options on the stock. This represents an increase of approximately 830
AtriCure, Inc. (ATRC) CEO Michael Carrel on Q1 2020 Results - Earnings Call Transcript
02:50am, Thursday, 30'th Apr 2020
AtriCure, Inc. (NASDAQ:ATRC) Q1 2020 Earnings Conference Call April 29, 2020, 16:30 ET Company Participants Lynn Lewis - Gilmartin Group Michael Carrel - CEO, P
Atricure (ATRC) Gets a Buy Rating from Oppenheimer
01:46am, Thursday, 30'th Apr 2020
Oppenheimer analyst Suraj Kalia maintained a Buy rating on Atricure (ATRC – Research Report) yesterday and set a price target
BTIG Believes Atricure (NASDAQ: ATRC) Still Has Room to Grow
12:35am, Thursday, 30'th Apr 2020
In a report released yesterday,
Marie Thibault
from BTIG reiterated a
Buy
rating on Atricure (
ATRC
–
Research Report
), with a price target of
$45.00
. The company’s shares closed last Wednesday
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $45
12:00am, Thursday, 30'th Apr 2020AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
09:25pm, Wednesday, 29'th Apr 2020
AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
09:25pm, Wednesday, 29'th Apr 2020
AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
AtriCure: 1Q Earnings Snapshot
08:15pm, Wednesday, 29'th Apr 2020
MASON, Ohio (AP) _ AtriCure Inc. (ATRC) on Wednesday reported a loss of $16.4 million in its first quarter.
On a per-share basis, the Mason, Ohio-based company said it had a loss of 42 cents. Losses,
AtriCure Reports First Quarter 2020 Financial Results
08:01pm, Wednesday, 29'th Apr 2020
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2020 financial results.
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
12:40pm, Wednesday, 29'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeu
